Clinical trial
Arsenic Trioxide in Treating Patients With Urothelial Cancer
NCT00009867 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00009867 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Urothelial Cancer |
| Official title | A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Enrollment | 35 |
| Start date | Dec 1, 2000 |
| Primary completion | Jun 1, 2004 |
| First posted | Dec 31, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: